Alnylam Pharma (ALNY) Tops Q3 EPS by 8c

Alnylam Pharma (NASDAQ: ALNY) reported Q3 EPS of ($1.58), $0.08 better than the analyst estimate of ($1.66). Revenue for the quarter came in at $125.9 million versus the consensus estimate of $120.75 million.

For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.

You May Also Be Interested In

• BMO Capital Starts Alnylam Pharmaceuticals (ALNY) at Outperform
• Youdao, Inc. (DAO) Tops Q2 EPS by 50c
• Deere shares climb as fiscal Q3 earnings and revenue top estimates